Wednesday, March 16, 2011

FivePrime inks potential $500M cancer drug deal with Human Genome Sciences

FivePrime Therapeutics Inc. will get $50 million upfront and as much as $445 million in future payments from Human Genome Sciences Inc. in a deal around FivePrime’s cancer-fighting genetically engineered protein drug.
The early-stage drug, called FP-1039, could be used against many types of cancers. It is in a Phase I trial but patients are being screened for a Phase II trial against a form of gynelogic cancer that attacks the lining of the uterus.

No comments:

Post a Comment

Post a Comment